a Department of Traumatic Orthopedics , the First Affiliated Hospital of Shenzhen University , Shenzhen , Guangdong Province , China.
b Shenzhen Key Laboratory of Tissue Engineering , Shenzhen , Guangdong Province , China.
J Drug Target. 2019 Jan;27(1):28-32. doi: 10.1080/1061186X.2018.1464011. Epub 2018 May 30.
Either osteoarthritis or sports-related injuries can lead to cartilage defects, whereas both chondrocyte self-renewal and conventional treatments face limitations. In cartilage regenerative medicine, growth factors are commonly used to induce chondrogenic differentiation of stem cells. However, application of growth factors is confined by some drawbacks. Emerging small molecules are regarded as an alternative for cartilage regeneration. A recently discovered small-molecule compound, kartogenin (KGN), has been proven to be a chondrogenic and chondroprotective agent and is more effective in inducing cartilage regeneration when compared with growth factors. KGN has been processed and applied in many forms, such as in intra-articular injection, in collaboration with growth factors, in incorporation in drug delivery systems, and in combination with scaffolds. Fortunately, progress has been achieved in KGN applications. The current review discusses the recent advances in KGN for cartilage regeneration and thus presents new concepts in cartilage repair in clinical settings.
无论是骨关节炎还是与运动相关的损伤都可能导致软骨缺陷,而软骨细胞的自我更新和传统治疗都面临着局限性。在软骨再生医学中,生长因子通常被用于诱导干细胞的软骨分化。然而,生长因子的应用受到一些缺点的限制。新兴的小分子被认为是软骨再生的一种替代方法。最近发现的一种小分子化合物,即 kartogenin(KGN),已被证明是一种软骨生成和软骨保护剂,并且在诱导软骨再生方面比生长因子更有效。KGN 已经以多种形式进行加工和应用,例如关节内注射、与生长因子联合应用、纳入药物输送系统以及与支架结合。幸运的是,KGN 的应用已经取得了进展。本文综述了 KGN 在软骨再生方面的最新进展,从而为临床软骨修复提出了新的概念。